| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T233 |
0-321 |
Sentence |
denotes |
In summary, although CQ/HCQ appeared to exhibit a favorable effect on COVID-19 patients in some initial studies of small numbers of patients, the most recent studies with larger sample sizes revealed that CQ/HCQ exhibited no significant improvement of disease but even an increased overall mortality in COVID-19 patients. |
| T234 |
322-447 |
Sentence |
denotes |
The studies on the combination of HCQ or CQ and macrolides (azithromycin or clarithromycin) also showed conflicting findings. |
| T235 |
448-638 |
Sentence |
denotes |
Therefore, caution should be taken regarding the use of CQ/HCQ treatment in COVID-19 due to the uncertainty of efficacy, the potential adverse effects and the various defects in the studies. |
| T236 |
639-902 |
Sentence |
denotes |
According to the Chinese Clinical Trial Registry (ChiCTR) (http://www.chictr.org.cn/index.aspx) and the International Clinical Trials Registry Platform (ICTRP) (https://www.who.int/ictrp/en/), currently, there are more than 200 ongoing clinical trials for CQ/HCQ. |
| T237 |
903-1065 |
Sentence |
denotes |
Current findings suggest that CQ/HCQ alone or in combination with macrolides should not be recommended for widespread use in COVID-19 (except in clinical trials). |
| T238 |
1066-1215 |
Sentence |
denotes |
Results from these ongoing prospective, randomized, controlled studies are required before these drugs are recommended for the treatment of COVID-19. |
